Testing a new protein-destroying treatment for advanced blood cancer

Plain-English translation of NCT07221500 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated July 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This study is testing a new medication called in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or stopped responding to other drugs. works differently than previous treatments—instead of just blocking a cancer-driving protein called BTK, it completely destroys it. Researchers want to see if this medication can shrink the cancer and how safe it is for patients to take long-term.

Many patients with CLL or SLL eventually stop responding to standard treatments, including BTK inhibitors and BCL-2 inhibitors. This trial exists to offer a new option for these patients with hard-to-treat disease, using a different approach that fully eliminates the BTK protein rather than just slowing it down.

Do you qualify?

You likely qualify if…

you are at least 18 years old
you have been diagnosed with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma
you have already received treatment with both a BTK inhibitor and a BCL-2 inhibitor in previous lines of therapy
you are in generally good health with an ECOG performance status of 0, 1, or 2 (able to do most normal activities)
you have adequate organ function and bone marrow function as shown by blood tests

You likely don't qualify if…

you have been previously treated with a BTK degrader
you have had CAR T-cell therapy or a bone marrow transplant within the past 90 days
you have had a blood clot, stroke, or brain bleed within the past 6 months
you are currently taking high-dose corticosteroids (more than 20 mg per day of prednisone or equivalent) except as premedication
you have received certain cancer therapies within 2 weeks of when the study would start

What participation looks like

You would take by mouth as a daily pill for as long as the treatment is working and you are tolerating it well. Throughout the study, you would have regular appointments for blood tests, physical exams, and scans to monitor how well the medication is working and check for any side effects. If your cancer stops responding to the treatment or you need to stop for another reason, you would continue to have follow-up cancer check-ups at regular intervals.

AI-generated summary from trial data · Jul 4, 2026 · Not medical advice

Trial locations(32 sites)

United States

City of Hope, Duarte, California

Colorado Blood Institute, Denver, Colorado

University of Miami, Coral Gables, Florida

Florida Cancer Specialists, Sarasota, Florida

Fort Wayne Oncology and Hematology, Fort Wayne, Indiana